Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeks Input On Acceptable Trial Design For Assessing Predictive Biomarkers

This article was originally published in The Pink Sheet Daily

Executive Summary

The Oncologic Drugs Advisory Committee will determine the legitimacy of retrospective trials used to determine predictive biomarkers during review of K-ras data for Erbitux and Vectibix.
Advertisement

Related Content

Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
Motesanib Gets Green Light In Lung Cancer Trial
Motesanib Gets Green Light In Lung Cancer Trial
Predictive Biomarkers Can Be Supported By Two Well-Conducted Retrospective Studies - FDA Advisors
Predictive Biomarkers Can Be Supported By Two Well-Conducted Retrospective Studies - FDA Advisors

Topics

Advertisement
UsernamePublicRestriction

Register

PS067117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel